Neeta Somaiah MD

Oncology•Houston, TX

Physician

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-8850
Fax+1 843-792-0644

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
St John's Episcopal Hospital-South ShoreInternship, Internal Medicine, 2002 - 2003
Maulana Azad Medical CollegeClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TX State Medical License 2012 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
SC State Medical License 2011 - 2015
PA State Medical License 2003 - 2014
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy Start of enrollment: 2011 May 01
Terminated
Phase 1
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2014 Oct 02
Completed
Phase 1, Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
COMPLETED
PHASE3
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
Completed
Phase 2
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma Start of enrollment: 2018 Sep 13
Completed
Phase 1
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
ACTIVE_NOT_RECRUITING
PHASE3
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Start of enrollment: 2020 Nov 26
RECRUITING
PHASE2
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study Start of enrollment: 2021 Jul 13
TERMINATED
PHASE2
Roles: Principal Investigator, Contact
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Start of enrollment: 2022 Aug 01
RECRUITING
PHASE1
Roles: Contact
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. Start of enrollment: 2024 Jun 18
RECRUITING
PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases.
Carlos Torrado, Elise Nassif Haddad, Neeta Somaiah, Pavlos Msaouel, Alexander J Lazar
Journal of Immunotherapy and Precision Oncology. 2025-05-01
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Sandra P D'Angelo, Mihaela Druta, Brian A Van Tine, David Liebner, Scott M Schuetze
Journal of Clinical Oncology. 2025-01-21
Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma.
Yining Jin, Zhiliang Jia, Xueqing Xia, Nancy B Gordon, Joseph A Ludwig
Frontiers in Immunology. 2025-01-01

Journal Articles

Characteristics and Outcomes of Patients with Advanced Sarcoma Enrolled in Early Phase Immunotherapy Trials
David S Hong, Neeta Somaiah, Anthony Conley, Shreyaskumar Patel, Filip Janku, Aung Naing, Kenneth Hess, Robert Benjamin, BioMed Central

Lectures

Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal Stromal TumorsSeptember 19th, 2024
Myxoid Liposarcoma: Diagnosis, Treatment and PrognosisSeptember 5th, 2024
Strong Support for Not Interrupting Imatinib Treatment in Advanced GISTAugust 20th, 2024
Join now to see all